Anat CohenDayag - Compugen President, Chief Executive Officer, Director
| CGEN Stock | ILA 760.00 38.70 5.37% |
CEO
Dr. Anat CohenDayag, Ph.D., was named Director, President and Chief Executive Officer for Compugen Ltd. effective February 10, 2014. Dr. Anat CohenDayag joined Compugen in 2002 as Director of Diagnostics, a position she held until 2005 at which time she became Vice President Diagnostic Biomarkers, a position she held until January 2007. From January 2007 until November 2008, Dr. CohenDayag served as Compugens Vice President, Biomarkers and Drug Targets, at which point she was appointed Vice President, Research and Development. In June 2009, Dr. CohenDayag was appointed, together with Mr. Martin Gerstel, as coChief Executive Officer of Compugen. In March 2010, upon Mr. Gerstels election as Chairman of the Board of Directors, Dr. CohenDayag was appointed as Compugens President and CEO. Prior to joining Compugen, she was head of research and development and member of the Executive Management at Mindsense Biosystems Ltd. Prior to Mindsense Biosystems Ltd., Dr. CohenDayag served as a scientist at the RD department of Orgenics Ltd since 2014.
| Age | 56 |
| Tenure | 10 years |
| Professional Marks | Ph.D |
| Phone | (972) 3 765 8555 |
| Web | www.cgen.com |
Compugen Management Efficiency
The company has return on total asset (ROA) of (0.2301) % which means that it has lost $0.2301 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4394) %, meaning that it generated substantial loss on money invested by shareholders. Compugen's management efficiency ratios could be used to measure how well Compugen manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 6 records | CEO Age | ||
| Kinneret Savitsky | BioLine RX | 48 | |
| Gil Efron | Purple Biotech | 51 | |
| Oren Hershkovitz | Enlivex Therapeutics | 46 | |
| Dror Mevorach | Enlivex Therapeutics | 63 | |
| Ofer Haviv | Evogene | 51 | |
| Itzhak Israel | Purple Biotech | 38 | |
Management Performance
| Return On Equity | -0.44 | |||
| Return On Asset | -0.23 |
Compugen Leadership Team
Elected by the shareholders, the Compugen's board of directors comprises two types of representatives: Compugen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Compugen. The board's role is to monitor Compugen's management team and ensure that shareholders' interests are well served. Compugen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Compugen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joshua Shemer, Independent External Director | ||
| Rivka Schwartz, VP Discovery | ||
| Paul Sekhri, Chairman of the Board | ||
| Martin Gerstel, Chairman of the Board | ||
| Zurit Levine, Vice President - Research and Discovery | ||
| Ari Krashin, Chief Financial Officer | ||
| Anat CohenDayag, President, Chief Executive Officer, Director | ||
| Ruth Arnon, Independent Director | ||
| Yair Aharonowitz, Independent External Director | ||
| Eran Dor, Gen Sec | ||
| Oliver Froescheis, Sr Devel | ||
| Alberto Sessa, Chief Officer | ||
| Michal Preminger, Director | ||
| Henry MD, VP Officer | ||
| Dov Hershberg, Director | ||
| Arie Ovadia, Independent External Director | ||
| Eran Perry, Director | ||
| Sanford Zweifach, Director | ||
| Gilead Halevy, Director | ||
| Yvonne Naughton, Head Communications | ||
| Kinneret Savitsky, Director | ||
| Henry Adewoye, Chief Medical Officer | ||
| Dorit Amitay, VP HR | ||
| JeanPierre Bizzari, Director | ||
| John Hunter, VP of Antibody RandD and Site Head of Compugen USA Inc |
Compugen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Compugen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.44 | |||
| Return On Asset | -0.23 | |||
| Current Valuation | 12.53 M | |||
| Shares Outstanding | 86.62 M | |||
| Shares Owned By Insiders | 5.50 % | |||
| Shares Owned By Institutions | 27.56 % | |||
| Price To Book | 1.13 X | |||
| Price To Sales | 46.89 X | |||
| Revenue | 6 M | |||
| Gross Profit | 5.32 M |
Pair Trading with Compugen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Compugen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Compugen will appreciate offsetting losses from the drop in the long position's value.Moving against Compugen Stock
| 0.68 | ARAD | Arad Investment Indu | PairCorr |
| 0.61 | ISRS | Isras Investment | PairCorr |
The ability to find closely correlated positions to Compugen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Compugen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Compugen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Compugen to buy it.
The correlation of Compugen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Compugen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Compugen moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Compugen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Compugen. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Compugen Stock refer to our How to Trade Compugen Stock guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Complementary Tools for Compugen Stock analysis
When running Compugen's price analysis, check to measure Compugen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compugen is operating at the current time. Most of Compugen's value examination focuses on studying past and present price action to predict the probability of Compugen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compugen's price. Additionally, you may evaluate how the addition of Compugen to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Stocks Directory Find actively traded stocks across global markets |